Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
Image Credit: NewsBytes
Pfizer and BioNTech have begin the clinical trial for a vaccine against the Omicron variant of coronavirus, the companies said on Tuesday. The trial will test the shot for safety, tolerability, and the level of immune response it would trigger. The companies could be ready to file for a regulatory approval of the vaccine by March, according to Pfizer CEO Albert Bourla.